Acute Myeloid Leukemia Pipeline Assessment 2021 report covers Unmet Needs, Key Opportunities, and Major Players

Loading...
Loading...

Los Angeles, USA, Feb. 15, 2021 (GLOBE NEWSWIRE) -- Acute Myeloid Leukemia Pipeline Assessment 2021 report covers Unmet Needs, Key Opportunities, and Major Players 


DelveInsight highlights recent progress and expected entry of Acute Myeloid Leukemia emerging therapies, including all phases of drug developments 

DelveInsight's "Acute Myeloid Leukemia Pipeline Insight'' report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Acute Myeloid Leukemia pipeline landscape. It comprises Acute Myeloid Leukemia pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Acute Myeloid Leukemia therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Acute Myeloid Leukemia pipeline products.   

Some of the significant Acute Myeloid Leukemia Pipeline Report Highlights 

  • Key players that are developing the drugs for the treatment of Soft Tissue Sarcoma include- Rafael Pharmaceuticals, Moleculin Biotech, BioSight, Abbvie, Jazz Pharmaceuticals, Amgen, AstraZeneca, Menarini Group, Polaris Group, Innovent Biologics, Helsinn Healthcare, Actinium Pharmaceuticals, Arog Pharmaceuticals, BerGenBio, and many others.
  • In December 2020, Rafael Pharmaceuticals announced that the USFDA has granted Fast Track designation for the Company's lead compound, CPI-613 (devimistat), for the treatment of acute myeloid leukemia (AML). The U.S. Food and Drug Administration (FDA) has given Rafael approval to initiate pivotal clinical trials in pancreatic cancer and acute myeloid leukemia (AML), and has designated CPI-613® as an orphan drug for the treatment of pancreatic cancer, AML, Myelodysplastic syndromes (MDS), peripheral T-cell lymphoma and Burkitt's lymphoma. The EMA has granted orphan drug designation to CPI-613® for pancreatic cancer and AML.
  • Results from an ongoing Phase 2b study, demonstrate that aspacytarabine treatment of AML patients is safe and well-tolerated, enabling delivery of high doses of cytarabine to older and unfit patients, leading to durable responses and prolonged survival. In December 2020, Biosight announced the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation to aspacytarabine (BST-236) for the treatment of acute myeloid leukemia (AML). Aspacytarabine was granted FDA Fast Track Designation for first-line treatment of AML patients unfit for standard chemotherapy, and Orphan Drug Designation.
  • In July 2020, Amgen initiated Phase-I clinical trials of AMG 330 in Acute myeloid leukemia (Combination therapy, Second-line therapy, or greater) in the USA (IV) (NCT04478695)

Request for sample pages @ Acute Myeloid Leukemia Pipeline Overview


Acute Myeloid Leukemia or Acute Myelogenous Leukemia (AML) is a type of blood cancer. Acute Myeloid Leukemia causes include a DNA mutation in the stem cells in the bone marrow. The mutation causes the stem cells to produce many more white blood cells than needed. It is the most common in older people. 

Acute Myeloid Leukemia treatment comprises chemotherapy, sometimes along with a targeted therapy drug. A stem cell transplant might follow this. Other drugs (besides standard chemotherapy drugs) may treat people with acute promyelocytic leukemia (APL). The most common remission induction regimens for AML include a drug called cytarabine, most often given continuously for seven days through an intravenous (IV) line. 


Acute Myeloid Leukemia Pipeline Therapeutics

  • CPI-613 (Devimistat) : Rafael Pharmaceuticals

Rafael's first-in-class clinical lead compound, CPI-613® (devimistat), targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. CPI-613® is being evaluated in multiple Phase I, I/II, II, and III clinical studies as a single agent, as well as in combination with standard drug therapies, in patients diagnosed with advanced solid tumors or blood cancers. The drug is in phase 3 of clinical trials for Acute Myeloid Leukemia and has received Fast Track designation for Acute myeloid leukemia [IV, Infusion] (Combination therapy, Recurrent, Refractory metastatic disease, Second-line therapy or greater) in the USA. 

  • Bemcentinib: BerGenBio

Bemcentinib (BGB324) is a potent, selective, and orally bioavailable AXL inhibitor and the most-advanced selective AXL inhibitor in clinical trials. The BGBC003 trial is a Phase Ib/II multi-center open-label study of bemcentinib in combination with cytarabine (part B2) and decitabine (part B3) in patients with AML who are unsuitable for intensive chemotherapy as a result of advanced age or existing-comorbidities.

  • Aspacytarabine : BioSight

Aspacytarabine (BST-236 ) is a novel proprietary anti-metabolite. It is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine, enabling delivery of high cytarabine doses to leukemia patients with lower systemic exposure to the free drug. Results from an ongoing Phase 2b study, demonstrate that aspacytarabine treatment of AML patients is safe and well-tolerated, enabling delivery of high doses of cytarabine to older and unfit patients, leading to durable responses and prolonged survival.

  • Annamycin liposomal : Moleculin Biotech

Annamycin is an anthracycline being developed  for the treatment of relapsed or refractory acute myeloid leukemia or AML. Annamycin is a unique next-generation liposome formulated anthracycline (also referred to in the literature as "L-Annamycin") that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms that often defeat currently approved anthracyclines. The drug is currently in phase I/II of clinical trials for the treatment of relapsed or refractory Acute Myeloid Leukemia.


For further product profiles, request @ Acute Myeloid Leukemia Pipeline Landscape 


Scope of Acute Myeloid Leukemia Pipeline Drug  Insight  

  • Coverage: Global 
  • Major Players: 100+ Key Players
  • Prominent Players: Rafael Pharmaceuticals, Moleculin Biotech, BioSight, Abbvie, Jazz Pharmaceuticals, Amgen, AstraZeneca, Astex Pharmaceuticals, Menarini Group, Polaris Group, Innovent Biologics, Helsinn Healthcare, Actinium Pharmaceuticals, Arog Pharmaceuticals, BerGenBio, and many others.  
  • Key Drugs Profiles: 100+ Products
  • Phases:  
    • Acute Myeloid Leukemia Therapies Late-stage (Phase III)  
    • Acute Myeloid Leukemia Therapies (Phase II)
    • Acute Myeloid Leukemia Therapies (Phase I) 
    • Acute Myeloid Leukemia Therapies Pre-clinical stage and Discovery candidates 
    • Discontinued and Inactive candidates 
  • Molecule Types:  
    • Small molecule
    • Gene therapy  
    • Stem cell therapy  
  • Mechanism of Action:
    • Protease inhibitors 
    • Immunomodulatory 
    • Multiple kinase inhibitor
  • Route of Administration:
    • Oral
    • Inhalation 
    • Subcutaneous 
    • Intravenous
  • Product Types:
    • Monotherapy
    • Combination 


Key Questions regarding Current Acute Myeloid Leukemia Treatment Landscape and Emerging Therapies Answered in the Pipeline Report    

  • What are the current options for Acute Myeloid Leukemia treatment?
  • How many companies are developing therapies for the treatment of Acute Myeloid Leukemia? 
  • How many Acute Myeloid Leukemia emerging therapies are in the early-stage, mid-stage, and late stages of development for the treatment of Acute Myeloid Leukemia?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Acute Myeloid Leukemia market? 
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Acute Myeloid Leukemia?  
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Acute Myeloid Leukemia therapies? 
  • What are the key designations that have been granted for the emerging therapies for Acute Myeloid Leukemia? 
  • How many patents are granted and pending for the emerging therapies for the treatment of Acute Myeloid Leukemia? 

Table of Contents

1Acute Myeloid Leukemia Introduction
2Acute Myeloid Leukemia Executive Summary
3Acute Myeloid Leukemia Overview
4Acute Myeloid Leukemia Analytical Perspective In-depth Commercial Assessment
5Acute Myeloid Leukemia Pipeline Therapeutics
5.1Acute Myeloid Leukemia Late Stage Products (Phase III)
5.1.1CPI-613: Rafael Pharmaceuticals
5.1.2Uproleselan: GlycoMimetics Incorporated
5.2Acute Myeloid Leukemia Mid Stage Products (Phase II)
5.2.1BST 236: BioSight Ltd.
5.3Acute Myeloid Leukemia Early Stage Products (Phase I/II)
5.3.1Annamycin liposomal: Moleculin Biotech
5.4Early Stage Products (Phase I)
5.4.1ABBV-744: Abbvie
6Acute Myeloid Leukemia Therapeutic Assessment
7Acute Myeloid Leukemia Inactive Products
8Company-University Collaborations (Licensing/Partnering) Acute Myeloid Leukemia Analysis
9Acute Myeloid Leukemia Key Companies
10Acute Myeloid Leukemia Key Products
11 Acute Myeloid Leukemia Unmet Needs
12Acute Myeloid Leukemia Market Drivers and Barriers
13Acute Myeloid Leukemia Future Perspectives and Conclusion
14Acute Myeloid Leukemia Analyst Views
15Appendix
16About DelveInsight
















Loading...
Loading...



Get customized pipeline report @ Acute Myeloid Leukemia Drug Treatment


Related Reports 

DelveInsight's Acute Myeloid Leukemia Market Insights, Epidemiology and Market Forecast 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.


DelveInsight's Acute Myeloid Leukemia (AML) - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Acute Myeloid Leukemia (AML) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


DelveInsight's Relapsed Chronic Lymphocytic Leukemia (CLL) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.


DelveInsight's ATCL Market report 2030 delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market trends in 7MM.


DelveInsight's Indolent Lymphoma - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.


DelveInsight's Peripheral T-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed understanding of historical and forecasted epidemiology.  


DelveInsight's Basal Cell Carcinoma (Basal Cell Epithelioma) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.


DelveInsight's Kaposi's Sarcoma Market Insights, Epidemiology and Market Forecast 2030 report provides an overview of the disease & an understanding of historical and forecasted epidemiology.


DelveInsight's Oligodendroglioma - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.


DelveInsight's Chronic Inducible Urticaria Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology.


DelveInsight's Corneal Ulcer - Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology.


About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.  


Contact Us:
Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Loading...
Loading...
Posted In: Health CareAnalyst RatingsPress Releasestechnical analysis
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...